aTyr Pharma Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -13.13 M-15.42 M-13.89 M-20.48 M-12.2 M -61.99 M Mittelzufluss aus Investitionstätigkeit -6.08 M-4.42 M3.3 M-20.38 M16.44 M -5.05 M Zahlungsströme aus der Finanzierungstätigkeit 18.84 M18.63 M17.9 M29.62 M-131 K 66.01 M Freier Cashflow -13.16 M-15.42 M-13.9 M-20.51 M-12.23 M -62.06 M

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.